Kodiak Sciences Inc. (KOD)
NASDAQ: KOD · IEX Real-Time Price · USD
+0.120 (4.76%)
At close: Jun 21, 2024, 4:00 PM
+0.030 (1.14%)
After-hours: Jun 21, 2024, 7:52 PM EDT

Company Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions.

The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.

Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc.
Kodiak Sciences logo
Country United States
Founded 2009
IPO Date Oct 4, 2018
Industry Biotechnology
Sector Healthcare
Employees 107
CEO Dr. Victor Perlroth M.D.

Contact Details

1200 Page Mill Rd
Palo Alto, California 94304
United States
Phone 650-281-0850
Website kodiak.com

Stock Details

Ticker Symbol KOD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001468748
CUSIP Number 50015M109
ISIN Number US50015M1099
Employer ID 27-0476525
SIC Code 2836

Key Executives

Name Position
Dr. Victor Perlroth M.D. Co-Founder, Chairman, Chief Executive Officer and President
John A. Borgeson CPA, M.B.A. Senior Vice President, Chief Financial Officer and Secretary
Dr. Michael S. Louie Ph.D. Senior Vice President of Digital Transformation and Chief Information Officer
Dr. Hong Liang Senior Vice President of Discovery Medicine
Dr. Stephen Raillard Ph.D. Senior Vice President of Chemical Development and Manufacturing
Almas Qudrat M.Sc. Senior Vice President of Quality Operations
Dr. J. Pablo Velazquez-Martin M.D. Senior Vice President of Clinical Research and Development
Tracy Chien Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Jun 6, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
May 15, 2024 8-K Current Report
Apr 23, 2024 ARS Filing
Apr 23, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2024 DEF 14A Other definitive proxy statements
Mar 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 28, 2024 10-K Annual Report
Mar 28, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals